We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
155 hedge funds and large institutions have $805M invested in Esperion Therapeutics in 2021 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 54 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
0% more capital invested
Capital invested by funds: $803M → $805M (+$1.94M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
1% less funds holding
Funds holding: 157 → 155 (-2)
8.04% less ownership
Funds ownership: 110.77% → 102.73% (-8%)
19% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 54
58% less call options, than puts
Call options by funds: $8.35M | Put options by funds: $19.9M
Holders
155
Holders Change
-2
Holders Change %
-1.27%
% of All Funds
2.72%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
21
Increased
44
Reduced
54
Closed
23
Calls
$8.35M
Puts
$19.9M
Net Calls
-$11.6M
Net Calls Change
-$8.09M
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.1M |
| 2 |
Swedbank
Stockholm,
Sweden
|
+$6.4M |
| 3 |
Millennium Management
New York
|
+$5.42M |
| 4 |
Citigroup
New York
|
+$4.54M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.81M |
